Introduction {#sec1-1}
============

Colorectal cancer (CRC) ranks the third most commonly cancer in males and the second in females, with an estimation of 71,830 men and 65,000 women diagnosed with colorectal cancer in 2014 (Siegel et al., 2014; Torre et al., 2015). Although the incidence rates of CRC decreased by approximately 3% per year during the past decades in western countries (Siegel et al., 2014), with the progressive 'westernization' of lifestyles, the incidence rates of CRC in China is sharply increasing (Chen et al., 2016). Although some environmental factors were established to play an important role in the etiology of CRC, it is estimated that approximately 35% of CRC risk may be attributable to inherited factors (Lichtenstein et al., 2000). Previous genome-wide association study (GWAS) have identified nearly 20 genetic loci in Asian associated with CRC susceptibility (Jia et al., 2013; Zhang et al., 2014; Wang et al., 2016; Zeng et al., 2016), however, could only explain a small fraction of the heritability. Therefore, more variants, especially functional variants with low-frequency still need to be explored.

Transcription factors are proteins that controls the rate of transcription of genetic information form DNA to mRNA by binding to a specific DNA sequence. In turn, they regulate the expression of genes and paly a very important role in both cell activity and tumor genesis. A better understanding of the regulatory factors that contribute in the development of CRC could provide new insights into precision medicine of this disease. The E2F transcription factor family is a crucial group of transcription factors that involved in the cell cycle regulation and carcinogenesis (Chen et al., 2009; Polager and Ginsberg, 2009). There are eight genes in this family (E2F1\~E2F8) and three of them are activators (E2F1, E2F2 and E2F3a). Missense variants, that change the amino acid of proteins, may alter the function of transcription factors and lead to a dysregulation of downstream genes. Thus, we conjecture that missense variants in E2F family genes may associate with CRC susceptibility.

In the present study, we searched for missense variants in the E2F transcription factors family (E2F1\~E2F8) and performed a case-control study to test whether these variants is associated with CRC risk.

Materials and Methods {#sec1-2}
=====================

Study subjects {#sec2-1}
--------------

This study consists of 1,055 CRC patients and 1,936 healthy controls. CRC patients were enrolled from People's Hospital of Zhengzhou University and Henan Provincial People's Hospital, Zhengzhou, China between January 1st, 2012 to November 30th, 2015. Health controls were selected from a community cancer screening program for early detection conducted in the same region during the same period as cases were collected. All participants were unrelated Han Chinese descent, and the inclusion criteria included pathologically confirmed primary CRC, without any radiotherapy or chemotherapy treatment prior to blood samples collected. The informed consent was obtained from every participant at recruitment and peripheral blood samples and demographic characteristics such as gender, age and ethnicity were collected by interviewers. This study was conducted under the approval of the Institutional Review Board of Zhengzhou University.

SNP selection and genotyping {#sec2-2}
----------------------------

We searched for missense variant in E2F transcription factor family genes (E2F1\~E2F8) using Ensembl (<http://asia.ensembl.org/>). rs2075995 at E2F2 and rs3829295 at E2F7 with MAF in Chinese Han Beijing (CHB) \> 0.01 were selected for genotyping. Genotyping were performed using genomic DNA extracted from 2 ml peripheral blood sample collected from each participant at recruitment. SNPs were genotyped by Taqman SNP Genotyping Assay (Applied Biosystems). The PCR primers and probes for genotyping rs2075995 and rs3829295 were 5'-GAG GAT ATC TCT TGT TGG CCT TGT-3'/5'-GAC CTG GGA AGC AGC AAC AG-3', 5'-FAM-CTG GAT GAG CTG GTC-MGBNFQ-3'/5'-HEX-CTG GAT GAG ATG GTC-MGBNFQ-3' and 5'-AGC TCA GGG CTA ACA GGA TGT C-3'/5'-AAA GGC AAA GTA GGG AAT ATG AAG AC-3', 5'-FAM-CCT TAC CTT GGG CAC GA-MGBNFQ-3'/5'-HEX-TTA CCT TGG GCA TGA C-MGBNFQ-3'. Several genotyping quality controls were implemented, including (i) the case and control samples were mixed in the plates, and persons who performed the genotyping assay were not aware of case or control status, (ii) positive and negative (no DNA) samples were included on every 384-well assay plate, and (iii) we further employed the direct sequencing of PCR products to replicate sets of 50 randomly selected, TaqMan-genotyped samples for the two SNPs and the accordance between the two methods was 100%.

Statistical analysis {#sec2-3}
--------------------

Odds ratios (ORs) and 95% confidence intervals (CIs) adjusted for age and sex gender were used to assess the strength of associations between selected polymorphisms and CRC risk by using unconditional multivariate logistic regression analysis. All statistical analyses were performed using SAS software (version 9.1; SAS Institute, Cary, NC), with a significance level of 0.05. All tests were two-sided.

Results {#sec1-3}
=======

Characteristic of Study Subjects {#sec2-4}
--------------------------------

The distributions of selected demographic characteristics including sex gender and age of the CRC patients and healthy controls were summarized in [Table 1](#T1){ref-type="table"}. The present study included 1,055 CRC patients and 1,936 gender matched healthy controls. There were 66.9% and 62.4% males in cases and controls, respectively. The average age of cases and controls were 60.5 and 64.8, respectively.

###### 

Summary of Characteristics of Study Subjects

                           Cases (n=1,055)   Controls (n=1,936)
  ------------------------ ----------------- --------------------
  Age (years), mean±S.D.   60.5 ± 12.8       64.8 ± 8.9
  Gender, n (%)                              
   Male                    706 (66.9)        1208 (62.4)
   Female                  349 (33.1)        728 (37.6)

Association between Missense SNPs in E2F family Genes and CRC Risk {#sec2-5}
------------------------------------------------------------------

Missense variant in E2F transcription factor family genes (E2F1\~E2F8) were searched. SNPs with global minor allele frequency (MAF)\>0.001 were listed ([Table 2](#T2){ref-type="table"}). Two SNPs (rs2075995 at E2F2 and rs3829295 at E2F7) with MAF in Chinese Han Beijing (CHB) \> 0.01 were selected for genotyping.

###### 

Genetic Variants in Exon Region of E2F Family Genes with Global Minor Allele Frequency \>0.001

  Chr      SNP             Position       Gene       Minor allele   Global MAF   CHB MAF      SIFT      PolyPhen
  -------- --------------- -------------- ---------- -------------- ------------ ------------ --------- -----------
  20       rs3213176       33676869       E2F1       T              0.012        0.000        1.0       0.01
  20       rs149272498     33677168       E2F1       C              0.001        0.000        0.2       0.045
  20       rs144481343     33677203       E2F1       T              0.001        0.000        0.9       0.003
  20       rs3213173       33677440       E2F1       T              0.006        0.000        0.1       0.013
  20       rs35385772      33678328       E2F1       T              0.013        0.000        1.0       0.002
  20       rs145741678     33680374       E2F1       T              0.002        0.000        0.1       0.564
  20       rs560305222     33680399       E2F1       T              0.001        0.000        0.2       0.21
  20       rs574523664     33686231       E2F1       T              0.001        0.000        1.0       0.000
  1        rs114788023     23516368       E2F2       T              0.004        0.000        0.4       0.002
  1        rs116576730     23516451       E2F2       A              0.003        0.000        0.3       0.124
  1        rs139052092     23519074       E2F2       A              0.001        0.000        0.0       0.838
  **1**    **rs2075995**   **23520972**   **E2F2**   **A**          **0.355**    **0.413**    **0.2**   **0.62**
  1        rs2229297       23521037       E2F2       T              0.006        0.000        0.1       0.008
  1        rs41306580      23521042       E2F2       A              0.001        0.000        0.2       0.025
  1        rs116694174     23521045       E2F2       A              0.001        0.000        0.0       0.097
  1        rs3218125       23530550       E2F2       T              0.001        0.000        0.0       0.959
  6        rs577488642     20402458       E2F3       G              0.002        0.000        0.0       0.153
  6        rs189058327     20402579       E2F3       T              0.008        0.000        0.3       0.001
  6        rs4134982       20490197       E2F3       A              0.003        0.000        0.4       0.013
  6        rs115470365     20490212       E2F3       T              0.002        0.000        0.4       0.001
  16       rs377030974     67195911       E2F4       A              0.001        0.005        0.4       0.001
  16       rs201338753     67195926       E2F4       A              0.001        0.005        0.5       0.002
  8        rs4150841       85177473       E2F5       C              0.029        0.000        0.9       0.000
  8        rs187526876     85209401       E2F5       C              0.001        0.000        0.6       0.001
  2        rs574653171     11447654       E2F6       G              0.001        0.000        0.0       0.000
  2        rs142815155     11447668       E2F6       A              0.001        0.000        0.0       0.000
  2        rs141189123     11450078       E2F6       T              0.005        0.000        1.0       0.002
  12       rs146918336     77024094       E2F7       C              0.001        0.000        0.8       0.001
  12       rs310831        77025561       E2F7       T              0.042        0.000        1.0       0.000
  12       rs566695974     77025683       E2F7       A              0.001        0.000        0.0       0.424
  12       rs560349395     77025706       E2F7       A              0.002        0.000        0.1       0.007
  12       rs532446600     77025757       E2F7       T              0.002        0.000        0.0       0.221
  12       rs34429867      77027946       E2F7       C              0.004        0.000        0.1       0.004
  12       rs36110778      77028089       E2F7       G              0.006        0.000        0.8       0.000
  **12**   **rs3829295**   **77029839**   **E2F7**   **C**          **0.008**    **0.0485**   **1.0**   **0.001**
  12       rs73133236      77029847       E2F7       A              0.001        0.000        0.0       0.219
  12       rs114349810     77030151       E2F7       T              0.003        0.000        0.1       0.019
  12       rs201813841     77033069       E2F7       G              0.001        0.000        0.7       0.062
  12       rs139349075     77033913       E2F7       C              0.002        0.000        0.0       0.013
  12       rs148596563     77033971       E2F7       T              0.001        0.000        0.7       0.002
  12       rs147478050     77044696       E2F7       C              0.001        0.000        0.0       0.661
  12       rs61754233      77046043       E2F7       C              0.007        0.000        0.7       0.235
  12       rs200583330     77055922       E2F7       T              0.001        0.005        0.0       0.925
  12       rs310791        77056010       E2F7       A              0.144        0.005        1.0       0.000
  12       rs149646617     77056111       E2F7       G              0.003        0.000        0.1       0.081
  12       rs61744271      77064629       E2F7       A              0.002        0.000        0.0       0.17
  11       rs137938238     19224728       E2F8       C              0.008        0.000        0.3       0.003
  11       rs145907915     19225288       E2F8       G              0.001        0.000        0.4       0.003
  11       rs793274        19225738       E2F8       C              0.02         0.000        0.4       0.041
  11       rs148337173     19225740       E2F8       C              0.001        0.000        0.0       1.000
  11       rs80272893      19229879       E2F8       A              0.001        0.000        0.1       0.98
  11       rs150203629     19230787       E2F8       A              0.001        0.000        0.0       0.462
  11       rs77599073      19230828       E2F8       G              0.015        0.000        0.3       0.05
  11       rs541607823     19234783       E2F8       C              0.001        0.000        0.2       0.005
  11       rs201855427     19234818       E2F8       G              0.001        0.005        0.7       0.002
  11       rs141999878     19234829       E2F8       A              0.001        0.000        0.0       0.99
  11       rs144450449     19235058       E2F8       C              0.002        0.000        0.1       0.734
  11       rs562521751     19237988       E2F8       T              0.001        0.000        0.1       0.463
  11       rs200312339     19238051       E2F8       T              0.001        0.000        0.6       0.005

Note, SNP, single nucleotide polymorphism; MAF, minor allele frequency; CHB, Chinese Han Beijing; SIFT is an algorithm which predicts whether an amino acid substitution affects protein function. SNPs with CHB MAF \>0.01 are in bold.

The genotype frequencies of the two selected SNPs and their associations with CRC risk were showed in [Table 3](#T3){ref-type="table"}. We did not observe any significant associations between rs2075995 at E2F2 and CRC susceptibility (TG vs. TT: OR=0.88, 95% CI: 0.75-1.04, P=0.135; GG vs. TT: OR=0.85, 95% CI: 0.67-1.08, P=0.189). However, we identified a missense SNP (rs382929) in E2F7 significantly associated with CRC susceptibility. Compared with TT genotype carriers, CT genotype and CT+CC genotype carriers were associated with risk of CRC with OR being 0.61 (95% CI: 0.44-0.85, P=0.003) and 0.61 (95% CI: 0.44-0.84, P=0.003), respectively.

###### 

Association between Two Exonic SNPs in E2F Family Genes and Risk of CRC in a Chinese Population

  SNP         Chr   Position   Gene   Genotype   CasesNo. (%)   ControlsNo. (%)   OR (95% CI)^[a](#t3f1){ref-type="table-fn"}^   P^[a](#t3f1){ref-type="table-fn"}^
  ----------- ----- ---------- ------ ---------- -------------- ----------------- ---------------------------------------------- ------------------------------------
  rs3829295   12    77423619   E2F7   TT         1,001 (94.9)   1,779 (91.9)      1.0 (Reference)                                
                                      TC         53 (5.0)       153 (7.9)         0.6 (0.4-0.8)                                  0.003
                                      CC         1 (0.1)        4 (0.2)           0.4 (0.1-3.8)                                  0.445
                                      TC+CC      54 (5.1)       157 (8.1)         0.6 (0.4-0.8)                                  0.003
  rs2075995   1     23847464   E2F2   TT         427 (40.5)     716 (37.0)        1.0 (Reference)                                
                                      TG         496 (47.0)     952 (49.2)        0.9 (0.7-1.0)                                  0.135
                                      GG         132 (12.5)     268 (13.8)        0.8 (0.7-1.1)                                  0.189
                                      TG+GG      628 (59.5)     1,220 (63.0)      0.9 (0.7-1.0)                                  0.093

, Calculated by logistic regressionmodel adjusted for gender and age

Stratified Analysis of Missense SNPs in E2F Family Genes and CRC Risk {#sec2-6}
---------------------------------------------------------------------

We performed stratified analyses by age and gender to evaluate the effects of variant genotypes on the risk of CRC ([Table 4](#T4){ref-type="table"}). Among the males, rs3829295 significantly associated with CRC susceptibility with an odds ratio of 0.56 (95% CI: 0.38-0.83, P= 0.004). However, the association were not observed for females (OR= 0.73, 95% CI: 0.43-1.22, P=0.232). When stratified by age, rs3829295 were significantly associated with CRC risk in both younger (\< 65 years) and older (≥ 65 years) participants with the OR being 0.59 (95% CI: 0.36-0.97, P=0.037) and 0.64 (95% CI: 0.43-0.96, P=0.031), respectively. For rs2075995, no significant associations were observed in stratified analyses.

###### 

Association of rs3829295 and CRC Risk Stratified by Gender and Age

  SNP         Male               *P*      Female             *P*
  ----------- ------------------ -------- ------------------ --------
  rs3829295   0.56 (0.38-0.83)   0.0038   0.73 (0.43-1.22)   0.2315
  rs2075995   0.95 (0.83-1.10)   0.5099   0.82 (0.68-1.01)   0.0569
              \> 65 years                 ≤ 65 years         
              OR (95% CI)        *P*      OR (95% CI)        *P*
  rs3829295   0.59 (0.36-0.97)   0.0368   0.64 (0.43-0.96)   0.0311
  rs2075995   0.92 (0.77-1.09)   0.3375   0.89 (0.77-1.03)   0.1217

Discussion {#sec1-4}
==========

In this hospital-based case-control study, we explored the association between missense variants in E2F transcription factors family and CRC susceptibility in 1,055 CRC patients and 1,936 controls. We found the frequency of the TC/CC genotypes of the rs3829295 were significantly lower than that of TT genotypes, especially in males. The results from the present study suggest thatrs3829295 T\>C polymorphism in E2F7 was significant associated with CRC risk, indicating an important role of E2F7 in CRC carcinogenesis.

The E2F7 gene is located at chromosome 12q21.2, containing 14 exons. As a member of E2F transcription factor family, E2F7 play an essential role in the regulation of cell cycle progression (Di Stefano et al., 2003). However, in contrast to the E2F activators (eg. E2F1 and E2F2), E2F7 can block the E2F-dependent activation of a subset of E2F target genes as well as mitigate cellular proliferation of mouse embryo fibroblasts (de Bruin et al., 2003). It was also reported that E2F7 and E2F8 works as a unique repressive arm of the E2F transcriptional network that controls the E2F1-p53 apoptotic axis (Li et al., 2008; Liu et al., 2013). E2F7 and E2F8 expression is induced in response to DNA damage, which is partially dependent on P53 (Zalmas et al., 2008; Aksoy et al., 2012; Carvajal et al., 2012). Accumulating evidence showed that E2F7 may act as a tumor suppressor in multiple types of cancer by blocking cell proliferation (de Bruin et al., 2003; Endo-Munoz et al., 2009; Mitxelena et al., 2016; Thurlings et al., 2016).

E2F7 has two DNA binding domains and binds to the E2F DNA binding consensus site independently of DP co-factors (Logan et al., 2004). A mutational analysis indicates that the integrity of both DNA-binding domains is required for cell cycle delay and transcriptional modulation (Logan et al., 2004). However, the rs3829295 T\>C polymorphism cause a 626th amino acid change (Met \> Val), not an amino acid change in the DNA binding domain of E2F7. Although not lead to a direct alteration to the DNA binding capacity of E2F7, the variant may function through other ways, such as influencing on the formation of E2F7 homodimer (Logan et al., 2004). Significant association between this variant and CRC risk with a relatively high effect size (OR=0.61 in dominant model) was observed in this study. The high effect size and not been identified by previous GWAS explain by its relatively low frequency in Chinese population (CHB MAF = 0.0485) and potential important function. The association was significant especially in males but not females, indicating a gender disparities for CRC. This results all indicated that further functional analysis is worthy to be performed to elucidate the relationship between rs3829295 and CRC in the future.

In summary, through a case-control study in a Chinese Han population, we find a significant association between E2F7 missense variant rs3829295 and CRC susceptibility, especially in males. This results expand our insights of CRC carcinogenesis and provide more evidence for the precision medicine of this disease.
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